The Brigham and Women's Hospital, Inc.

Beth Israel Hospital Assoc.

Mark A Goldberg

Carlo Brugnara

Yide Jiang

William C Faquin

Margot S Kruskall

Linda A Chambers

Michael Vasconcelles

Andrew P Levy

The present invention is directed to DNA elements that enhance cellular gene expression in response to anaerobic growth or the presence of certain inducing agents. The enhancer element may be incorporated into expression vectors and used to increase the production of recombinant proteins.

Hypoxia responsive transcription enhancer element from yeast

Transition metal ions enhance the ability of the body to increase vascularization, particularly for revascularizing damaged tissues, apparently because they enhance expression of the vegF gene, so as to increase VEGF levels. According, hypoxic tissue damage can be treated or prophylactically reduced by administering a composition comprising a transition metal ion capable of stimulating vascularization. Treatment can be accomplished using compositions of matter which include a transition metal ion in a sterile, biologically compatible carrier, packaged as a unit dosage effective to increase vascularization in hypoxic tissue. For systemic administration, the transition metal ion is formulated at a concentration that is non-toxic and ineffective to increase vascularization in non-hypoxic tissue. For local administration, the transition metal ions are formulated in a slow-releasing carrier to release the transition metal ions continually over a prolonged period in an amount effective to increase vascularization locally. For example, for topical application, the composition may be a salve, a gel, or a patch. For internal slow release or for topical application, the composition may be formulated in a slow release matrix.

Induction of vascular endothelial growth factor (VEGF) by transition

The present invention is an in-vitro blood assay method for determining the past and/or present use of exogenous erythropoietin by a living subject. The blood assay method detects, identifies, and determines the consequences of using an exogenous erythropoietin to generate an increase in red blood cell production in the living subject and provides a methodology by which to detect and determine both surreptitious as well as authorized therapeutic uses and applications of erythropoietin.

In-vitro method for determining a surreptitious use of exogenous

The invention is directed to the administration of Interleukin 6 for the purpose of enhancing endogenous erythropoietin levels in vitro and in vivo. The invention further encompasses methods of treatment of disorders characterized by, or including, erythropoietin deficiency. Such disorders include the anemias of chronic inflammation, renal failure, AIDS, and malignancy.

Growing community of inventors

Boston, MA, United States of America

Mark A Goldberg